Does Rallies show 13F holders for ELVN?

Yes. Rallies tracks hedge fund and 13F ownership data for ELVN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ELVN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ELVN. It does not provide personalized investment advice.

ELVN (Enliven Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Enliven Therapeutics, Inc. Common Stock (ELVN) is a publicly traded Healthcare sector company. As of May 20, 2026, ELVN trades at $41.87 with a market cap of $2.41B and a P/E ratio of -22.91. ELVN moved +4.27% today. Year to date, ELVN is +175.21%; over the trailing twelve months it is +140.85%. Its 52-week range spans $13.30 to $48.53. Analyst consensus is strong buy with an average price target of $57.14. Rallies surfaces ELVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ELVN stock?

Hedge funds tracked by Rallies that own ELVN include Orbimed Advisors and Duquesne Family. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Enliven Therapeutics, Inc. Common Stock.

ELVN Key Metrics

Key financial metrics for ELVN
Metric	Value
Price	$41.87
Market Cap	$2.41B
P/E Ratio	-22.91
EPS	$-1.83
Dividend Yield	0.00%
52-Week High	$48.53
52-Week Low	$13.30
Volume	567.19K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-103.69M
Gross Margin	0.00%

Top Hedge Funds Holding ELVN

Orbimed Advisors holds 7.96M shares of ELVN, changed +0.00% as of Mar 31, 2026.
Duquesne Family holds 947.40K shares of ELVN, changed +104.62% as of Sep 30, 2025.

Latest ELVN News

Enliven reports Q1 net loss, $452M runway and H2 2026 Phase 3 start — May 7, 2026
Enliven's ELVN-001 Yields 69% MMR Rate in 60-Patient Phase 1b Trial, Phase 3 Set for H2 2026 — Jan 8, 2026

Recent ELVN Insider Trades

Collins Helen Louise sold 140 (~$6.41K) on Apr 17, 2026.
Collins Helen Louise sold 2.42K (~$114.64K) on Apr 17, 2026.
Collins Helen Louise sold 2.44K (~$117.30K) on Apr 17, 2026.

ELVN Analyst Consensus

8 analysts cover ELVN: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $57.14.

Common questions about ELVN

Who owns ELVN stock?: Hedge funds tracked by Rallies that own ELVN include Orbimed Advisors and Duquesne Family. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Enliven Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for ELVN?: Yes. Rallies tracks hedge fund and 13F ownership data for ELVN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ELVN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ELVN. It does not provide personalized investment advice.